You are here: Industry Insights > AstraZeneca

News List

Ionis Pharma, AstraZeneca to advance new drug for NASH biospectrumasia
April 12, 2018
AstraZeneca will pay a $30 million license fee to Ionis. AstraZeneca will be responsible for further development and commercialization of Ionis's lead candidate
Ionis Licenses NASH Drug to AstraZeneca contractpharma
April 10, 2018
Ionis Pharmaceuticals, Inc. has licensed IONIS-AZ6-2.5-LRx, or AZD2693, to AstraZeneca following its advancement into development.
FDA accepts AstraZeneca’s licensing application for leukaemia drug pharmaceutical-technology
April 09, 2018
AstraZeneca and MedImmune, its global biologics research and development arm, have announced that the FDA has accepted the Biologics License Application (BLA) for moxetumomab pasudotox for adult patients with hairy cell leukaemia (HCL).
AstraZeneca's oncology drugs receive regulatory boost biospectrumasia
April 08, 2018
US FDA has granted priority review for its AstraZeneca's candidate that treats leukemia while EU has accepted the Marketing Authorisation Application ) for Lynparza
USFDA accepts BLA for moxetumomab pasudotox by AstraZeneca biospectrumasia
April 08, 2018
The FDA has granted the moxetumomab pasudotox BLA Priority Review status with a Prescription Drug User Fee Act date set for the third quarter of 2018
USFDA accepts BLA for moxetumomab pasudotox by AstraZeneca biospectrumasia
April 08, 2018
The FDA has granted the moxetumomab pasudotox BLA Priority Review status with a Prescription Drug User Fee Act date set for the third quarter of 2018
AstraZeneca’s Lokelma receives EU approval biospectrumasia
April 02, 2018
Lokelma is a highly-selective, oral potassium-removing agent. The approval is supported by data from three double-blind, placebo-controlled trials and one open-label trial, where patients with hyperkalaemia were treated for up to 12 months
AstraZeneca Tops the Pharmaceutical Innovation Index for the First Time biospace
March 29, 2018
The Pharmaceutical Innovation Index measures, scores and celebrates a company's ability to deliver innovation to patients, by objectively evaluating performance based on a rolling five year period (2012-2017)
EU approves AZ’s potential blockbuster hyperkalaemia drug pharmaphorum
March 26, 2018
AstraZeneca’s hyperkalaemia treatment Lokelma has been approved in Europe, a relief to the company after two years of delay to the potential blockbuster.
AstraZeneca Shows Off New Farxiga Data for Diabetes Patients with Chronic Kidney Disease biospace
March 21, 2018
AstraZeneca Pharmaceuticals LP’s drug Farxiga could receive a new indication for a subset of diabetes patients based on Phase III data that was released today.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page